Aliskiren Hemifumarate; Hydrochlorothiazide Patent Expiration
Aliskiren Hemifumarate; Hydrochlorothiazide is Used for lowering high blood pressure. It was first introduced by Noden Pharma Dac
Aliskiren Hemifumarate; Hydrochlorothiazide Patents
Given below is the list of patents protecting Aliskiren Hemifumarate; Hydrochlorothiazide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tekturna Hct | US8618172 | Galenical formulations of organic compounds | Jul 13, 2028 | Noden Pharma |
| Tekturna Hct | US9023893 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar 03, 2022
(Expired) | Noden Pharma |
| Tekturna Hct |
US5559111 (Pediatric) | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan 21, 2019
(Expired) | Noden Pharma |
| Tekturna Hct | US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul 21, 2018
(Expired) | Noden Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate; Hydrochlorothiazide's patents.
Latest Legal Activities on Aliskiren Hemifumarate; Hydrochlorothiazide's Patents
Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate; Hydrochlorothiazide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 12 Jun, 2023 | US9023893 |
| Maintenance Fee Reminder Mailed Critical | 26 Dec, 2022 | US9023893 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jun, 2021 | US8618172 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2018 | US9023893 |
| Recordation of Patent Grant Mailed Critical | 05 May, 2015 | US9023893 |
| Patent Issue Date Used in PTA Calculation Critical | 05 May, 2015 | US9023893 |
| Email Notification Critical | 16 Apr, 2015 | US9023893 |
| Issue Notification Mailed Critical | 15 Apr, 2015 | US9023893 |
| Post Issue Communication - Certificate of Correction | 09 Apr, 2015 | US8618172 |
| Application Is Considered Ready for Issue Critical | 03 Apr, 2015 | US9023893 |
Aliskiren Hemifumarate; Hydrochlorothiazide's Family Patents
